{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T10:43:24Z","timestamp":1781001804159,"version":"3.54.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,9,18]],"date-time":"2013-09-18T00:00:00Z","timestamp":1379462400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"published-print":{"date-parts":[[2013,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Acute behavioural disturbance (ABD) is a common problem in psychiatry and both physical restraint and involuntary parenteral sedation are often required to control patients. Although guidelines are available, clinical practice is often guided by experience and there is little agreement on which drugs should be first-line treatment for rapid tranquilisation. This study aimed to investigate sedation for ABD in an acute mental healthcare unit, including the effectiveness and safety of high dose sedation.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>A prospective study of parenteral sedation for ABD in mental health patients was conducted from July 2010 to June 2011. Drug administration (type, dose, additional doses), time to sedation, vital signs and adverse effects were recorded. High dose parenteral sedation was defined as greater than the equivalent of 10\u00a0mg midazolam, droperidol or haloperidol (alone or in combination), compared to patients receiving 10\u00a0mg or less (normal dose). Effective sedation was defined as a fall in the sedation assessment tool score by two or a score of zero or less. Outcomes included frequency of adverse drug effects, time to sedation\/tranquilisation and use of additional sedation.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Parenteral sedation was given in 171 cases. A single drug was given in 96 (56%), including droperidol (74), midazolam (19) and haloperidol (3). Effective sedation occurred in 157 patients (92%), and the median time to sedation was 20\u00a0min (Range: 5 to 100\u00a0min). The median time to sedation for 93 patients receiving high dose sedation was 20\u00a0min (5-90\u00a0min) compared to 20\u00a0min (5-100\u00a0min; p\u2009=\u20090.92) for 78 patients receiving normal dose sedation. Adverse effects occurred in 16 patients (9%); hypotension (14), oxygen desaturation (1), hypotension and oxygen desaturation (1). There were more adverse effects in the high dose sedation group compared to the normal dose group [11\/93 (12%) vs. 5\/78 (6%); p\u2009=\u20090.3]. Additional sedation was given in 9 of 171 patients (5%), seven in the high dose and two in the normal dose groups.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Large initial doses of sedative drugs were used for ABD in just over half of cases and additional sedation was uncommon. High dose sedation did not result in more rapid or effective sedation but was associated with more adverse effects.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1471-244x-13-225","type":"journal-article","created":{"date-parts":[[2013,9,18]],"date-time":"2013-09-18T05:01:17Z","timestamp":1379480477000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["A prospective study of high dose sedation for rapid tranquilisation of acute behavioural disturbance in an acute mental health unit"],"prefix":"10.1186","volume":"13","author":[{"given":"Leonie","family":"Calver","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Drinkwater","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey K","family":"Isbister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,9,18]]},"reference":[{"key":"1408_CR1","volume-title":"Patient Settings and the Emergency Departments","author":"National Institute of Clinical Excellence","year":"2005","unstructured":"National Institute of Clinical Excellence: Violence: The short term management of distiurbed\/violent Behaviourin the Psychiatric. Patient Settings and the Emergency Departments. 2005, London: Clinical Guideline"},{"issue":"1","key":"1408_CR2","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.psychres.2010.12.024","volume":"189","author":"CM Cornaggia","year":"2011","unstructured":"Cornaggia CM, Beghi M, Pavone F, Barale F: Aggression in psychiatry wards: a systematic review. Psychiatry Res. 2011, 189 (1): 10-20. 10.1016\/j.psychres.2010.12.024.","journal-title":"Psychiatry Res"},{"issue":"3","key":"1408_CR3","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1176\/ps.2009.60.3.406","volume":"60","author":"B Stubbs","year":"2009","unstructured":"Stubbs B: Physical injuries from restrictive interventions. Psychiatr Serv. 2009, 60 (3): 406-10.1176\/appi.ps.60.3.406.","journal-title":"Psychiatr Serv"},{"key":"1408_CR4","unstructured":"Allen MH, Currier GW, Hughes DH, Reyes Harde M, Docherty JP: The Expert Consensus Guideline Series. Treatment of behavioral emergencies. Postgrad Med. 2001, 1-88. quiz 89-90, Spec No"},{"key":"1408_CR5","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1192\/pb.bp.108.023762","volume":"34","author":"S Brown","year":"2010","unstructured":"Brown S, Chhina N, Dye S: Use of psychotropic medication in seven English psychiatric intensive care units. The Psychiatrist. 2010, 34: 130-135. 10.1192\/pb.bp.108.023762.","journal-title":"The Psychiatrist"},{"key":"1408_CR6","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1097\/00131746-200511001-00002","volume":"11","author":"MH Allen","year":"2005","unstructured":"Allen MH, Currier GW, Carpenter D, Ross R, Docherty JP: The Expert Consensus Guideline Series. Treatment of behavioral emergencies 2005. J Psychiatr Pract. 2005, 11: 5-112.","journal-title":"J Psychiatr Pract"},{"issue":"4","key":"1408_CR7","doi-asserted-by":"publisher","first-page":"219","DOI":"10.2165\/00023210-200216040-00002","volume":"16","author":"GW Currier","year":"2002","unstructured":"Currier GW, Trenton A: Pharmacological treatment of psychotic agitation. CNS Drugs. 2002, 16 (4): 219-228. 10.2165\/00023210-200216040-00002.","journal-title":"CNS Drugs"},{"key":"1408_CR8","first-page":"4","volume":"15","author":"J Brattaglia","year":"1997","unstructured":"Brattaglia J, Moss S, Rush J, Kang J, Mendoza R, Leedom L, Dubin W, McGlynn C, Goodman L: Haliperidol, Lorazepam, or both for Psychotic Agitation? A Multiceter,Prospective, Double-Blind, Emergency Department Study. Am J Emerg Med. 1997, 15: 4-","journal-title":"Am J Emerg Med"},{"key":"1408_CR9","volume-title":"Mental Health for Emergency Departments-A Reference Guide","author":"Mental Health Drug and Alcohol Office","year":"2009","unstructured":"Mental Health Drug and Alcohol Office: Mental Health for Emergency Departments-A Reference Guide. 2009, Sydney: NSW Department of Health"},{"key":"1408_CR10","volume-title":"British National Formulary","author":"British Medical Association and the Royal Pharmaceutical Society of Great Britain","year":"2001","unstructured":"British Medical Association and the Royal Pharmaceutical Society of Great Britain: British National Formulary. 2001, London"},{"issue":"Suppl 2","key":"1408_CR11","doi-asserted-by":"publisher","first-page":"S96","DOI":"10.1590\/S1516-44462010000600006","volume":"32","author":"C Mantovani","year":"2010","unstructured":"Mantovani C, Migon MN, Alheira FV, Del-Ben CM: Management of the violent or agitated patient. Rev Bras Psiquiatr. 2010, 32 (Suppl 2): S96-103.","journal-title":"Rev Bras Psiquiatr"},{"key":"1408_CR12","volume-title":"Cochrane Database Syst Rev","author":"A Chakrabarti","year":"2007","unstructured":"Chakrabarti A, Whicher E, Morrison M, Douglas-Hall P: 'As required' medication regimens for seriously mentally ill people in hospital. Cochrane Database Syst Rev. 2007, 3: CD003441"},{"issue":"6","key":"1408_CR13","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1111\/j.1742-6723.2011.01484.x","volume":"23","author":"LA Calver","year":"2011","unstructured":"Calver LA, Stokes B, Isbister GK: Sedation assessment tool to score acute behavioural disturbance in the emergency department. Emerg Med Australas. 2011, 23 (6): 732-740. 10.1111\/j.1742-6723.2011.01484.x.","journal-title":"Emerg Med Australas"},{"issue":"4)","key":"1408_CR14","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.annemergmed.2010.05.037","volume":"56","author":"GK Isbister","year":"2010","unstructured":"Isbister GK, Calver LA, Page CB, Stokes B, Bryant JL, Downes MA: Randomized controlled trial of intramuscular droperidol versus midazolam for violence and acute behavioral disturbance: the DORM study. Ann Emerg Med. 2010, 56 (4)): 392-401. e391","journal-title":"Ann Emerg Med"},{"issue":"1","key":"1408_CR15","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/1471-227X-10-14","volume":"10","author":"L Calver","year":"2010","unstructured":"Calver L, Downes M, Page C, Bryant J, Isbister G: The impact of a standardised intramuscular sedation protocol for acute behavioural disturbance in the emergency department. BMC Emerg Med. 2010, 10 (1): 14-10.1186\/1471-227X-10-14.","journal-title":"BMC Emerg Med"},{"issue":"4","key":"1408_CR16","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1097\/00004714-200108000-00006","volume":"21","author":"K Meehan","year":"2001","unstructured":"Meehan K, Zhang F, David S, Tohen M, Janicak P, Small J, Koch M, Rizk R, Walker D, Tran P, et al: A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania. J Clin Psychopharmacol. 2001, 21 (4): 389-397. 10.1097\/00004714-200108000-00006.","journal-title":"J Clin Psychopharmacol"},{"issue":"5","key":"1408_CR17","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1001\/archpsyc.59.5.441","volume":"59","author":"A Breier","year":"2002","unstructured":"Breier A, Meehan K, Birkett M, David S, Ferchland I, Sutton V, Taylor CC, Palmer R, Dossenbach M, Kiesler G, et al: A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. Arch Gen Psychiatry. 2002, 59 (5): 441-448. 10.1001\/archpsyc.59.5.441.","journal-title":"Arch Gen Psychiatry"},{"issue":"4","key":"1408_CR18","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/S0893-133X(01)00365-7","volume":"26","author":"KM Meehan","year":"2002","unstructured":"Meehan KM, Wang H, David SR, Nisivoccia JR, Jones B, Beasley CM, Feldman PD, Mintzer JE, Beckett LM, Breier A: Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: a double-blind, randomized study in acutely agitated patients with dementia. Neuropsychopharmacology. 2002, 26 (4): 494-504. 10.1016\/S0893-133X(01)00365-7.","journal-title":"Neuropsychopharmacology"},{"issue":"7","key":"1408_CR19","first-page":"298","volume":"45","author":"M Resnick","year":"1984","unstructured":"Resnick M, Burton BT: Droperidol vs. haloperidol in the initial management of acutely agitated patients. J Clin Psychiatry. 1984, 45 (7): 298-299.","journal-title":"J Clin Psychiatry"},{"issue":"11","key":"1408_CR20","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1177\/070674370304801102","volume":"48","author":"P Wright","year":"2003","unstructured":"Wright P, Lindborg SR, Birkett M, Meehan K, Jones B, Alaka K, Ferchland-Howe I, Pickard A, Taylor CC, Roth J, et al: Intramuscular olanzapine and intramuscular haloperidol in acute schizophrenia: antipsychotic efficacy and extrapyramidal safety during the first 24 hours of treatment. Can J Psychiatry. 2003, 48 (11): 716-721.","journal-title":"Can J Psychiatry"},{"key":"1408_CR21","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1192\/bjp.bp.110.081513","volume":"198","author":"MD Lesem","year":"2011","unstructured":"Lesem MD, Tran Johnson TK, Riesenberg RA, Feifel D, Allen MH, Fishman R, Spyker DA, Kehne JH, Cassella V: Rapid acute treatment of agitation in individuals with schizophrenia: multicentre, randomised, placebo-controlled study of inhaled loxapine. Br J Psychiatry. 2011, 198: 51-58. 10.1192\/bjp.bp.110.081513.","journal-title":"Br J Psychiatry"},{"issue":"7","key":"1408_CR22","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1176\/appi.ajp.158.7.1149","volume":"158","author":"P Wright","year":"2001","unstructured":"Wright P, Birkett M, David SR, Meehan K, Ferchland I, Alaka KJ, Saunders JC, Krueger J, Bradley P, San L, et al: Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia. Am J Psychiatry. 2001, 158 (7): 1149-1151. 10.1176\/appi.ajp.158.7.1149.","journal-title":"Am J Psychiatry"},{"issue":"12","key":"1408_CR23","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1176\/ps.50.12.1553","volume":"50","author":"EMD Binder RL","year":"1999","unstructured":"Binder RL EMD: Contemporary practices in managing acute violent patients in 20 psychiatric emergency rooms. Psychiatr Serv. 1999, 50 (12): 1553-1554.","journal-title":"Psychiatr Serv"},{"issue":"3","key":"1408_CR24","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.ajem.2004.02.027","volume":"22","author":"ML Martel","year":"2004","unstructured":"Martel ML: Ziprasidone for sedation of the agitated ED patient. Am J Emerg Med. 2004, 22 (3): 238-","journal-title":"Am J Emerg Med"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-244X-13-225.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-244X-13-225\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-244X-13-225","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-244X-13-225.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T01:30:37Z","timestamp":1630546237000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpsychiatry.biomedcentral.com\/articles\/10.1186\/1471-244X-13-225"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9,18]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["1408"],"URL":"https:\/\/doi.org\/10.1186\/1471-244x-13-225","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,9,18]]},"assertion":[{"value":"13 February 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2013","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2013","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"225"}}